Nivolumab and rHuPH20

BIOLOGICAL2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Advanced Solid TumorsClear Cell Renal Cell Carcinoma

Phase 1

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

RecruitingNCT06697197

Bristol-Myers SquibbAdvanced Solid Tumors

Start: 2025-02-17End: 2029-01-05Target: 413Updated: 2026-02-03

Phase 3

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Active, not recruitingNCT04810078

Bristol-Myers SquibbClear Cell Renal Cell Carcinoma

Start: 2021-05-21End: 2027-05-10Updated: 2025-10-09

Related Papers

Model‐Informed Drug Development of Subcutaneous Nivolumab: Comparison of Pharmacokinetic Analysis Methodologies Using Clinical Trial Simulation

CPT Pharmacometrics & Systems Pharmacology2025-09-24

Subcutaneous versus intravenous nivolumab for renal cell carcinoma.

2024-09-1510 citations

Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.

Journal of Clinical Oncology2024-06-012 citations

Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial.

Journal of Clinical Oncology2024-06-012 citations

A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.

Journal of Clinical Oncology2024-06-011 citations

Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.

Journal of Clinical Oncology2024-01-294 citations

616 Pharmacokinetics and safety of a subcutaneous formulation of nivolumab (NIVO SC) monotherapy: updated results from the phase 1/2 CheckMate 8KX study

Regular and Young Investigator Award Abstracts2023-10-31

Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.

Journal of Clinical Oncology2022-06-012 citations